Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PARKE-DAVIS SEEKING BENADRYL Rx-TO-OTC SWITCH FOR ANTIPRURITIC

Executive Summary

PARKE-DAVIS SEEKING BENADRYL Rx-TO-OTC SWITCH FOR ANTIPRURITIC use via a petition to amend the monograph for OTC antihistamine drug products. In an Aug. 31 submission to FDA, the firm's counsel (Washington-based Kleinfeld, Kaplan & Becker and Stovall & Spradlin) requested that the allowable indications for oral diphenhydramine be extended to include a claim for the relief of allergic itching. Oral diphenhydramine is currently Category I for symptoms of hay fever and the common cold. In support of the safety and efficacy of oral diphenhydramine as an OTC antipruritic, the submission points to Parke-Davis' approved NDA for Benadryl as a treatment of "uncomplicated allergic skin manifestations of urticaria and angioedema," and inclusion of the ingredient in the OTC antihistamine tentative final monograph (TFM). The submission also notes that switching the allergic itching indication to OTC status does not raise any safety issues related to dosing because the recommended prescription dose (25 mg to 50 mg three to four times daily) is identical to the dose recommended for relief of cold/hay fever symptoms in the antihistamine TFM. The firm is suggesting that the antihistamine final monograph permit oral diphenhydramine products to carry the indication: "For temporary relief of itching associated with hives, minor skin irritations, or rashes due to food or animal allergies, insect bites, inhaled allergens (dust, mold, spores), poison ivy, oak, or sumac, soaps, detergents, cosmetics, and jewelry." In addition to its use as an antihistamine, diphenhydramine has been switched to OTC status for use as a sleep-aid and as an antitussive. Both the antihistamine and nighttime sleep-aid switches were accomplished through the monograph procedures, while the drug's OTC use as an antitussive was approved via a supplement to Parke-Davis' Benadryl NDA. Discussing the firm's reasons for pursuing the switch through the monograph, the submission states: "The expeditious review and approval possible by following [the monograph] route furthers the statutory policy favoring direct public access to safe and effective self-medication. This policy is particularly important for a symptom as prevalent and widespread as itching associated with common minor allergic responses (e.g., insect bites, inhaled allergens, poison ivy, etc.)." To "require an NDA for OTC marketing," the filing continues, "would unduly and unnecessarily delay a clearly desirable result." The filing notes that if the switch is allowed, "the existing warnings [for diphenhydramine] on drowsiness and use in patients with glaucoma, prostatic hypertrophy, and asthma" discussed in the antihistamine TFM would apply to the antipruritic indication. In addition, the firm is recommending that the antihistamine TFM incorporate warnings required "for OTC topical antiprurities concerning discontinuing use and consulting a physician if the condition worsens or symptoms persist for more than seven days."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel